New combo therapy aims to wipe out early anal cancer
NCT ID NCT06493019
Summary
This study is testing a new combination of drugs and radiation for people with early-stage anal cancer. The goal is to see if adding an immunotherapy drug (pembrolizumab) to standard chemotherapy and radiation can more effectively eliminate the cancer. Participants will receive several months of treatment followed by a period of monitoring to see if the cancer returns.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact Email: •••••@•••••
Contact
-
University of Maryland
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Email: •••••@•••••
Contact
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.